According to BioNTech's balance sheet for the January-March period, the company, which made a net profit of 502.2 million euros in the first quarter of 2023, announced a net loss of 315.1 million euros in the January-March period of this year.
The company's net profit per share, which was 14.24 euros in the first quarter of last year, decreased to 2.05 euros in the same period of this year.
BioNTech's revenue decreased by 85 percent to 187.6 million euros in the first quarter of this year compared to the same period last year. The company had revenue of 1 billion 277 million euros in the first quarter of 2023.
In the company statement, it was stated that the change in financial results was due to the decline in the company's revenues from the sale of Covid-19 vaccines worldwide.
"BioNTech expects to achieve approximately 90 percent of its full-year revenues in the last months of 2024," the statement said, adding that the company is still working on another variant-adapted Covid-19 vaccine for the 2024/25 vaccination season.
According to the statement, the company, which shifted its focus to cancer drug development after the Covid-19 outbreak, plans to launch its first cancer drug in 2026.
In the field of infectious diseases, BioNTech has also started clinical tests for vaccine candidates against malaria, tuberculosis and tuberculosis.
"WE PLAN TO ACCELERATE OUR ACTIVITIES"
BioNTech Chief Executive Officer (CEO) and Co-Founder Prof. Dr. Uğur Şahin noted that they plan to develop and commercialize a variant-adapted Covid-19 vaccine for the rest of the year.
"We plan to accelerate our clinical development activities to realize the full potential of our oncology unit to become a commercial company with marketed drugs for cancer and infectious diseases," said Prof. Dr. Şahin.
